Verastem, Inc.

NASDAQ: VSTMHealthcare / Biotechnology / USA
1.90+0.0800+4.40%Vol 4 363 5911Y Perf -78.26%
Jun 19th, 2019 16:00
BID1.91 ASK1.93
Open1.82 Previous Close1.82
Pre-Market1.82 After-Trading1.95
 - -%  0.05 2.63%
Target Price
7.88 
Analyst Rating
Strong Buy 1.00
Potencial %
314.74 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/100/100 
Income Ranking
 —    -
Market Cap (mil)140 
Earnings Rating
Sell
Price Range Ratio 52wk %
8.05 
Earnings Date
9th May 2019

Today's Price Range

1.742.05

52wk Range

1.1610.35

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Month
23.38%
3 Months
-46.93%
6 Months
-44.12%
1 Year
-78.26%
3 Years
36.69%
5 Years
-80.61%

Name / TickerPriceChg.Chg.%
VSTM1.900.08004.40
AAPL197.87-0.5800-0.29
GOOG1 102.33-1.2700-0.12
MSFT135.690.53000.39
XOM75.32-0.4200-0.55
WFC45.65-0.4500-0.98
JNJ140.450.22000.16
FB187.48-0.9900-0.53
GE10.33-0.0900-0.86
JPM109.91-0.8000-0.72
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.46-0.51-10.87
Q04 2018-0.54-0.3731.48
Q03 2018-0.43-0.2932.56
Q02 2018-0.35-0.3014.29
Q01 2018-0.41-0.410.00
Q04 2017-0.38-0.43-13.16
Q03 2017-0.32-0.61-90.62
Q02 2017-0.34-0.36-5.88
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.49-6.52Negative
9/2019 QR-0.47-4.44Negative
12/2019 FY-1.97-5.91Negative
12/2020 FY-1.79-20.13Negative
Next Report Date-
Estimated EPS Next Report-0.46
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume4 363 591
Shares Outstanding (in ths.)73 877
Trades Count9 253
Dollar Volume7 948 208
Avg. Volume2 527 467
Avg. Weekly Volume3 569 685
Avg. Monthly Volume1 916 456
Avg. Quarterly Volume2 261 360
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
5 (100.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.25

Verastem, Inc.

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

CEO: Robert Forrester

Teplephone: +1 781 292-4200

Address: 117 Kendrick Street, Needham 02494, MA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

63%37%

Bearish Bullish

55%45%

News